Hagen Brett R 4

What Happened
Brett R. Hagen, Chief Accounting Officer of Kalaris Therapeutics (KLRS), sold 1,915 common shares on March 20, 2026 at $6.72 per share for proceeds of $12,869. He was also granted a derivative award (an option) on March 19, 2026 covering 60,800 shares with a $0 reported purchase price (i.e., a grant of equity subject to vesting).

Key Details

• Sale: 1,915 shares on 2026-03-20 at $6.72 each; total proceeds $12,869. Reported as an open market or private sale (code S).
• Grant: Option to acquire 60,800 shares reported 2026-03-19 (code A); reported price $0.00 (derivative award).
• Shares owned after transactions: filing updates beneficial ownership accordingly — the filing indicates the Reporting Person no longer holds the sold common shares and holds the 60,800-share option subject to vesting.
• Footnote F1: Prior Form 4 (filed 2025-03-27) mistakenly reported 1,925 shares; correct pre-transaction common-share count was 1,915 and was updated here.
• Footnote F2 (vesting): 25% of the 60,800 shares vest on March 19, 2027; the remainder vests in equal monthly installments over the following three years, subject to continuous service.
• Filing: Form 4 filed March 23, 2026 reporting the March 19–20 transactions.

Context

• The grant is a time‑based option award (derivative); it does not represent immediately vested common stock and provides future upside only if vesting and exercise occur. This was not an exercise-and-sell (cashless) transaction.
• Sales by officers can be routine (taxes, diversification, or other personal reasons); facts reported here are transactional and do not indicate insider motivation.